newsfilter
← Latest News
GlobeNewswire·

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage